Aurinia Pharmaceuticals (AUPH) Revenue (2019 - 2026)

Aurinia Pharmaceuticals' Revenue history runs 8 years deep, the most recent figure standing at $77.7 million for Q1 2026.

• Quarterly Revenue rose 24.4% year-over-year to $77.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $298.3 million (up 20.62% YoY) and the FY2025 annual result came in at $283.1 million, up 20.38% from the prior year.
• Revenue was $77.7 million for Q1 2026 at Aurinia Pharmaceuticals, up from $77.1 million in the prior quarter.
• Across five years, Revenue topped out at $77.7 million in Q1 2026 and bottomed at $21.6 million in Q1 2022.
• A 5-year average of $53.3 million and a median of $55.8 million in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue surged 2265.97% — and 2023, when it dropped 2.27%.
• Aurinia Pharmaceuticals' Revenue stood at $28.4 million in 2022, then surged by 58.59% to $45.1 million in 2023, then surged by 32.76% to $59.9 million in 2024, then rose by 28.81% to $77.1 million in 2025, then climbed by 0.77% to $77.7 million in 2026.
• Business Quant data shows AUPH's Revenue at $77.7 million in Q1 2026, $77.1 million in Q4 2025, and $73.5 million in Q3 2025.